Melanoma Clinical Trials in New York State

Showing 81-100 of 136 trials

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

NCT01227551

The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria \[irRECIST 1.1\] (revised Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1).

Malignant Melanoma

Viralytics57 participantsStarted Dec 2011

La Jolla, California, United States • San Francisco, California, United States • Miami Beach, Florida, United States +7 more locations

COMPLETEDPHASE3100 miles

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

NCT02714218

The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.

Melanoma

Bristol-Myers Squibb387 participantsStarted Apr 2016

Aurora, Colorado, United States • Tampa, Florida, United States • Fridley, Minnesota, United States +54 more locations

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma Trials in Other Cities

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

IMCgp100-401 Rollover Study

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Safety Study of MGA271 in Refractory Cancer

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Engaging Moms on Teen Indoor Tanning Through Social Media

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

Other Conditions in New York State